INSILICO (03696) has reached a multi-year research and development cooperation agreement worth $888 million with Shwe Ya in the field of anti-tumor drugs.

INSILICO (03696) announced that the group has reached a multi-year research and development cooperation agreement with the global independent pharmaceutical company Schviya, managed by a foundation. The cooperation is valued at up to $888 million and will make full use of the group's independently developed artificial intelligence platform Pharma.AI, focusing on challenging targets in the field of anti-tumor therapy to identify and develop new therapeutic drugs. According to the agreement, the group will be eligible to receive a maximum of $32 million in upfront payments and near-term research milestone payments, and will lead the use of artificial intelligence technology to discover and develop potential candidate drugs that meet established standards, while Schviya will share in the research and development costs and lead the subsequent clinical validation and commercialization process. Christophe Thurieau, Executive Director of the Schviya Research Institute, stated: "This collaboration demonstrates Schviya's commitment to using cutting-edge technology to address unmet medical needs and ultimately benefit patients, as well as our confidence in INSILICO's independently developed and validated artificial intelligence platform." Dr. Alex Zhavoronkov, founder, CEO, and chief business officer of INSILICO, said: "I am very excited about this collaboration, which shows that our artificial intelligence drug development capabilities and strengths are once again being recognized. As we further integrate generative artificial intelligence into various stages of the drug development value chain, I believe the future of pharmaceutical superintelligence is near, where AI intelligence can truly make decisions and design experiments, forming a virtuous cycle that accelerates drug development faster, smarter, and safer."